Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort.

IF 1.2 Q4 RHEUMATOLOGY

Reumatismo Pub Date : 2024-06-24 DOI:10.4081/reumatismo.2024.1608

E Molteni, C Pirone, F Ceccarelli, C Castellani, C Alessandri, M Di Franco, V Riccieri, F R Spinelli, R Priori, R Scrivo, F Conti

{"title":"Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort.","authors":"E Molteni, C Pirone, F Ceccarelli, C Castellani, C Alessandri, M Di Franco, V Riccieri, F R Spinelli, R Priori, R Scrivo, F Conti","doi":"10.4081/reumatismo.2024.1608","DOIUrl":null,"url":null,"abstract":"Objective: Data from trials demonstrated that abatacept (ABA) has a good safety and efficacy profile in treating rheumatoid arthritis. We have studied the retention rate of ABA in a real-life cohort of patients with rheumatoid arthritis.Methods: This is a monocentric, retrospective study including patients with rheumatoid arthritis classified by the American College of Rheumatology/European League Against Rheumatism 2010 criteria who started treatment with ABA. The Kaplan-Meier method was applied to evaluate the ABA retention rate.Results: This analysis was conducted on 161 patients [male/female 21/140, median age 65 years, interquartile range (IQR) 18.7, median disease duration 169 months, IQR 144.0]. 111 patients (68.9%) received ABA subcutaneously. ABA was associated with methotrexate in 61.9% of patients and was the first biological disease-modifying antirheumatic drug in 41%. We observed a median ABA survival of 66 months [95% confidence interval (CI) 57.3-74.7], with a retention rate of 88% at 6 months and 50.9% at 5 years. Drug survival was significantly higher in patients treated with ABA subcutaneously and in male patients (p=0.039 and p=0.018, respectively). Adjusted for main confounders, female gender was the main predictor of withdrawal (hazard ratio 5.1, 95% CI 1.2-21.3).Conclusions: Our study shows that better survival is associated with subcutaneous administration and male gender, confirming ABA effectiveness.","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatismo","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/reumatismo.2024.1608","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Data from trials demonstrated that abatacept (ABA) has a good safety and efficacy profile in treating rheumatoid arthritis. We have studied the retention rate of ABA in a real-life cohort of patients with rheumatoid arthritis.

Methods: This is a monocentric, retrospective study including patients with rheumatoid arthritis classified by the American College of Rheumatology/European League Against Rheumatism 2010 criteria who started treatment with ABA. The Kaplan-Meier method was applied to evaluate the ABA retention rate.

Results: This analysis was conducted on 161 patients [male/female 21/140, median age 65 years, interquartile range (IQR) 18.7, median disease duration 169 months, IQR 144.0]. 111 patients (68.9%) received ABA subcutaneously. ABA was associated with methotrexate in 61.9% of patients and was the first biological disease-modifying antirheumatic drug in 41%. We observed a median ABA survival of 66 months [95% confidence interval (CI) 57.3-74.7], with a retention rate of 88% at 6 months and 50.9% at 5 years. Drug survival was significantly higher in patients treated with ABA subcutaneously and in male patients (p=0.039 and p=0.018, respectively). Adjusted for main confounders, female gender was the main predictor of withdrawal (hazard ratio 5.1, 95% CI 1.2-21.3).

Conclusions: Our study shows that better survival is associated with subcutaneous administration and male gender, confirming ABA effectiveness.

查看原文本刊更多论文

类风湿关节炎患者在现实生活中的阿巴他赛保留率：单中心队列的结果。

目的：试验数据表明，阿巴他赛（ABA）在治疗类风湿关节炎方面具有良好的安全性和有效性。我们研究了类风湿关节炎患者队列中阿巴他赛普的保留率：这是一项单中心回顾性研究，研究对象包括根据美国风湿病学会/欧洲抗风湿联盟 2010 年标准分类的类风湿关节炎患者，他们都开始接受 ABA 治疗。采用卡普兰-梅耶法评估 ABA 的保留率：分析对象为 161 名患者[男性/女性 21/140，中位年龄 65 岁，四分位数间距 (IQR) 18.7，中位病程 169 个月，IQR 144.0]。111名患者（68.9%）皮下注射了ABA。在61.9%的患者中，ABA与甲氨蝶呤同时使用，在41%的患者中，ABA是第一种生物改变病情抗风湿药物。我们观察到，ABA 的中位生存期为 66 个月[95% 置信区间 (CI) 为 57.3-74.7]，6 个月和 5 年的保留率分别为 88% 和 50.9%。皮下注射 ABA 的患者和男性患者的药物存活率明显更高（分别为 p=0.039 和 p=0.018）。对主要混杂因素进行调整后，女性性别是预测停药的主要因素（危险比 5.1，95% CI 1.2-21.3）：我们的研究表明，皮下注射和男性性别与更好的存活率有关，证实了 ABA 的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reumatismo RHEUMATOLOGY-

CiteScore

2.10

自引率

7.10%

发文量

审稿时长

10 weeks

期刊介绍： Reumatismo is the official Journal of the Italian Society of Rheumatology (SIR). It publishes Abstracts and Proceedings of Italian Congresses and original papers concerning rheumatology. Reumatismo is published quarterly and is sent free of charge to the Members of the SIR who regularly pay the annual fee. Those who are not Members of the SIR as well as Corporations and Institutions may also subscribe to the Journal.